Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia

Henry Gerad; Merrill J. Egorin; Margaret Whitacre; David A. Van Echo; Joseph Aisner

doi:10.1007/BF00254197

Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia

Henry Gerad, Merrill J. Egorin, Margaret Whitacre, David A. Van Echo, Joseph Aisner

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Three patients with advanced refractory malignancies were treated with whole-body hyperthermia (WBH: 42-42.3° C) for 2 h during which time they also received an infusion of 60 or 80 mg/m² of cis-diamminedichloroplatinum II (DDP). Each patient developed an elevated serum creatinine (2.7-13.6 mg/dl), with maximum creatinine occurring between days 7 and 12 after treatment. WBH did not alter plasma or urinary pharmacokinetics of total or ultrafilterable platinum compared with pharmacokinetic data of the same or other patients given DDP euthermically. Although the mechanism of the renal damage is unclear, it appears that WBH can potentiate the nephrotoxic actions of DDP and that further study of this combination is not warranted.

Original language	English (US)
Pages (from-to)	162-166
Number of pages	5
Journal	Cancer chemotherapy and pharmacology
Volume	11
Issue number	3
DOIs	https://doi.org/10.1007/BF00254197
State	Published - Nov 1983
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/BF00254197

Cite this

@article{a0f4fd7209cc44f9aac0c69a400818be,

title = "Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia",

abstract = "Three patients with advanced refractory malignancies were treated with whole-body hyperthermia (WBH: 42-42.3° C) for 2 h during which time they also received an infusion of 60 or 80 mg/m2 of cis-diamminedichloroplatinum II (DDP). Each patient developed an elevated serum creatinine (2.7-13.6 mg/dl), with maximum creatinine occurring between days 7 and 12 after treatment. WBH did not alter plasma or urinary pharmacokinetics of total or ultrafilterable platinum compared with pharmacokinetic data of the same or other patients given DDP euthermically. Although the mechanism of the renal damage is unclear, it appears that WBH can potentiate the nephrotoxic actions of DDP and that further study of this combination is not warranted.",

author = "Henry Gerad and Egorin, {Merrill J.} and Margaret Whitacre and {Van Echo}, {David A.} and Joseph Aisner",

year = "1983",

month = nov,

doi = "10.1007/BF00254197",

language = "English (US)",

volume = "11",

pages = "162--166",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia

AU - Gerad, Henry

AU - Egorin, Merrill J.

AU - Whitacre, Margaret

AU - Van Echo, David A.

AU - Aisner, Joseph

PY - 1983/11

Y1 - 1983/11

N2 - Three patients with advanced refractory malignancies were treated with whole-body hyperthermia (WBH: 42-42.3° C) for 2 h during which time they also received an infusion of 60 or 80 mg/m2 of cis-diamminedichloroplatinum II (DDP). Each patient developed an elevated serum creatinine (2.7-13.6 mg/dl), with maximum creatinine occurring between days 7 and 12 after treatment. WBH did not alter plasma or urinary pharmacokinetics of total or ultrafilterable platinum compared with pharmacokinetic data of the same or other patients given DDP euthermically. Although the mechanism of the renal damage is unclear, it appears that WBH can potentiate the nephrotoxic actions of DDP and that further study of this combination is not warranted.

AB - Three patients with advanced refractory malignancies were treated with whole-body hyperthermia (WBH: 42-42.3° C) for 2 h during which time they also received an infusion of 60 or 80 mg/m2 of cis-diamminedichloroplatinum II (DDP). Each patient developed an elevated serum creatinine (2.7-13.6 mg/dl), with maximum creatinine occurring between days 7 and 12 after treatment. WBH did not alter plasma or urinary pharmacokinetics of total or ultrafilterable platinum compared with pharmacokinetic data of the same or other patients given DDP euthermically. Although the mechanism of the renal damage is unclear, it appears that WBH can potentiate the nephrotoxic actions of DDP and that further study of this combination is not warranted.

UR - http://www.scopus.com/inward/record.url?scp=0021016690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021016690&partnerID=8YFLogxK

U2 - 10.1007/BF00254197

DO - 10.1007/BF00254197

M3 - Article

C2 - 6685578

AN - SCOPUS:0021016690

SN - 0344-5704

VL - 11

SP - 162

EP - 166

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 3

ER -

Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this